Abrams et al., found that C-KIT overexpression was recognized in many cancers including gastrointestinal stromal tumors, small cell lung cancer, melanoma, non–small cell lung cancer, and AML, which raise the attention for using an anti-C-KIT antibody as a treatment protocol in these cancers [37]. This evidence concerns the gene KIT and small cell lung carcinoma.